Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development ...
A type of immunotherapy appears to be effective in treating a deadly subset of thyroid cancer, according to the results of a ...
Nivolumab-based treatment (N+AVD) improves progression-free survival in advanced-stage Hodgkin’s lymphoma patients compared ...
The combination of vidutolimod and nivolumab “stimulates a broad antitumor immune response,” according to researchers.
GlobalData on MSN2d
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancerCommittee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination therapy consisting of ...
Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...
SEC recommends approval of additional indication for BMS' anti-cancer drug nivolumab: Gireesh Babu, New Delhi Tuesday, November 19, 2024, 08:00 Hrs [IST] The Subject Expert Commit ...
Source: Getty Images Avelumab plus axitinib was associated with significantly longer progression-free survival than ...
MyChesCo on MSN3d
Promising New Data from Hepatitis B Trial by Arbutus and BarinthusArbutus Biopharma Corporation and Barinthus Biotherapeutics recently unveiled encouraging preliminary results from their ...
The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...
Medpage Today on MSN8d
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease ControlThe study added to a limited database about the effects of perioperative IO combinations, which have emerged as standard of ...
During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback